Accreditation Information

Accreditation
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (UAN 0245-0000-17-012-L01-P).

Nursing (ANCC)
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CE request form, statements of credit for physicians and nurses will be issued via email within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy®(NABP®) CPE Monitor electronic CE tracking system.

Needs Statement

Immune checkpoint inhibition (ICI) targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 pathway (PD-1/PD-L1) has dramatically improved the care of patients with many advanced malignancies.1 Although ICI targeting CTLA-4 and PD-1/PD-L1 shows a broad range of activity, there are cancer types that seem to be resistant to such therapy. Therefore, identifying biomarkers that predict response to therapy and the occurrence of immune-mediated adverse reactions is crucial to ensure optimal patient outcomes.2 Based on the ever-expanding knowledge about the mechanism of action of various cancer immunotherapy approaches, including ICI targeting CTLA-4 and PD-1/PD-L1, the use of combination therapies may be the next logical step to improve response rates, increase duration of responses, and potentially increase cure rates.1-3

Attendees of this Grand Rounds series will gain an appreciation of the current and emerging approaches to immune checkpoint blockade in selected types of solid tumors, as well as the current status and future prospects for development of robust prognostic and predictive biomarkers of response to immunotherapy.

References
1Ott PA, et al. J Immunother Cancer. 2017. 2Topalian SL. Nat Rev Cancer. 2016. 3Mahoney KM, et al. Nat Rev Drug Discov. 2015.

Objectives

At the conclusion of this knowledge-based activity, participants will be able to:

• Differentiate the mechanism of action and safety and efficacy of current and emerging immune checkpoint inhibitors used in selected types of solid tumors.
• Appraise the rationale and latest data for combined immune checkpoint blockade in selected types of solid tumors.
• Evaluate signs and symptoms of the immune-mediated adverse reactions associated with immune checkpoint blockade and strategies members of the healthcare team can employ to anticipate and effectively manage them.
• Assess utility of PD-L1 expression and other immune variables as prognostic and predictive biomarkers of response to immune checkpoint inhibitors used in selected types of solid tumors.

Target Audience

Oncology specialists (physicians, nurses, pharmacists) and other members of the oncology care team.

Faculty Disclosure

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD – has no relevant financial relationships to disclose in relation to the content of this activity.

Robert L. Ferris, MD, PhD – has disclosed that he is a consultant for Amgen, AstraZeneca/MedImmune, Benitec, Bristol-Myers Squibb, EMD Serono, Lilly, Merck, and Pfizer. He also receives grant/research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, and Venti Rx.

Naiyer A. Rizvi, MD – has disclosed that he is a consultant for AstraZeneca, Merck, Novartis, and Roche. He is also a major stock shareholder in Gritstone Oncology.

Authors/Presenters:
Sanjiv S. Agarwala, MD – has no relevant financial relationships to disclose in relation to the content of this activity.

Michael B. Atkins, MD – has disclosed that he is a consultant for Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche.

Arjun V. Balar, MD – has disclosed that he is a consultant for AstraZeneca/MedImmune, Genetech, Roche, Merck, and Pfizer. He also receives grant/research support from Genetech, Roche, and Merck.

Robert L. Ferris, MD, PhD – has disclosed that he is a consultant for Amgen, AstraZeneca/MedImmune, Benitec, Bristol-Myers Squibb, EMD Serono, Lilly, Merck, and Pfizer. He also receives grant/research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, and Venti Rx.

Brent Hanks, MD, PhD – has disclosed that he receives grant/research support from AstraZeneca, Merck, and OncoMed. He also is a major stock shareholder for Bellicum Pharmaceuticals.

Jason J. Luke, MD, FACP – has disclosed that he is a consultant for Actymthera, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Novartis, Merck, and 7 Hills. His institution receives grant/research support from AbbVie, Boston Biomedical, Bristol-Myers Squibb, Celldex, Corvus, Delcath, Five Prime, Genentech, Immunocore, Incyte, Intensity, MedImmune Macrogenics, Novartis, Pharmacyclics, Merck, and Tesaro.

Jose Lutzky, MD – has disclosed that he is a member of the speakers’ bureaus for Bristol-Myers Squibb and Novartis.

Isabella C. Glitza Oliva - MD, PhD - has no relevant financial relationships to disclose in relation to the content of this activity.

Sandip Patel, MD – has disclosed that he is a consultant for Bristol-Myers Squibb and Novartis; receives research/grant support from Bristol-Myers Squibb, Lilly, Fate, Incyte, MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery; and a member of the speakers’ bureaus for Boehringer Ingelheim and Merck.

Naiyer A. Rizvi, MD – has disclosed that he is a consultant for AstraZeneca, Merck, Novartis, and Roche. He is also a major stock shareholder in Gritstone Oncology.

Reviewers:
Marianne Davies DNP, ACNP, AOCNP – has disclosed that she is a member of the speakers’ bureaus for AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.

Adebayo Ogunniyi, PharmD, MPA, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.